JAMA journal quietly replaces diabetes drug commentary after learning co-author is working for drugmaker
JAMA Internal Medicine has replaced a commentary they published last week on the risks of two diabetes drugs, but you wouldn’t know the new version was a replacement. One change is a correction about whether Byetta and Januvia carry so-called “black box” warnings from the FDA. The original sentence: Because both drugs already carry US … Continue reading JAMA journal quietly replaces diabetes drug commentary after learning co-author is working for drugmaker